Latest Medical Breakthroughs Transforming Healthcare in 2024

The latest medical breakthroughs transforming healthcare in 2024 include the first FDA-approved CRISPR gene therapy, a surge in AI-enabled diagnostic devices, real progress on a personalized mRNA cancer vaccine, and an expanded global malaria vaccine rollout. On 8 December 2023, the FDA approved Casgevy, the first CRISPR-Cas9 gene-editing therapy, for sickle cell disease — a milestone that carried into 2024 as the therapy reached patients. This article covers what actually happened, with real sources, not vague hype.

Key Takeaways

• Casgevy, the first FDA-approved CRISPR-Cas9 gene therapy, was cleared on 8 December 2023 for sickle cell disease in patients 12 and older, per the FDA's own announcement.

• The FDA's official AI-Enabled Medical Devices list has grown past 1,200 authorized devices, with radiology accounting for the large majority.

• A personalized mRNA melanoma vaccine (mRNA-4157) combined with pembrolizumab showed a statistically significant improvement in recurrence-free survival in a Lancet-published phase 2b trial.

• The WHO's malaria vaccines (RTS,S and R21) reached children in 17 endemic countries in 2024, a first for a vaccine against this parasitic disease.

What Was the Biggest Gene Therapy Breakthrough of 2024?

The biggest gene therapy breakthrough carrying into 2024 was Casgevy (exagamglogene autotemcel), the first CRISPR-Cas9 gene-editing therapy approved by the FDA, cleared on 8 December 2023 for sickle cell disease in patients aged 12 and older with recurrent vaso-occlusive crises. The approval opened a one-time treatment option to an estimated 16,000 eligible patients in the US alone, according to the FDA's own press announcement, by editing a patient's own stem cells to increase fetal hemoglobin production.

This matters beyond sickle cell disease itself: Casgevy is proof that CRISPR-based gene editing can clear the FDA's approval bar for a genetic blood disorder, opening a regulatory pathway other gene-editing therapies for conditions like beta-thalassemia are now following.

Casgevy's treatment process itself illustrates why gene therapies like this remain complex, resource-intensive procedures rather than a simple injection:

1. Stem cells are collected from the patient's own blood.

2. The cells are edited outside the body using CRISPR-Cas9 to increase fetal hemoglobin production.

3. The patient undergoes conditioning chemotherapy to prepare the bone marrow to receive the edited cells.

4. The edited stem cells are reinfused via a one-time infusion.

5. Patients are monitored over months as the edited cells engraft and begin producing functional hemoglobin.

How Is AI Changing Medical Diagnostics?

AI is changing medical diagnostics primarily through imaging: the FDA's own Artificial Intelligence-Enabled Medical Devices list has grown past 1,200 authorized devices, with radiology accounting for roughly three-quarters of all AI-enabled device authorizations to date. These tools assist with detecting patterns in scans faster than manual review, though they support clinicians rather than replace physician judgment.

The pace of authorizations has accelerated sharply in recent years, reflecting how quickly AI-assisted imaging has moved from research demonstrations to devices used in real clinical settings.

Is There a Real Cancer Vaccine Breakthrough?

Yes — a personalized mRNA melanoma vaccine, mRNA-4157, combined with the immunotherapy drug pembrolizumab, showed a statistically significant improvement in recurrence-free survival compared to pembrolizumab alone in a randomised phase 2b trial published in The Lancet in February 2024. The trial reported an 18-month recurrence-free survival rate of 79% for the combination versus 62% for pembrolizumab alone, and Moderna and Merck's own longer-term follow-up data has since reported sustained reductions in recurrence and death risk.

This is meaningfully different from older, more speculative "cancer vaccine" claims: mRNA-4157 is individualized to each patient's own tumor mutations (a neoantigen approach), tested in a randomised trial, and published in a peer-reviewed journal — the kind of evidence trail worth looking for before trusting any cancer-breakthrough headline.

What Vaccine Progress Happened Globally in 2024?

The most significant global vaccine development of 2024 was the expanded rollout of the WHO-recommended malaria vaccines, RTS,S and R21, which reached children in 17 malaria-endemic countries during the year — the first time any vaccine against a parasitic disease has been deployed at this scale. Gavi-subsidized pricing brought both vaccines down to roughly $0.20 per dose for lower-resource countries, according to WHO's own reporting, addressing a disease that has historically killed hundreds of thousands of children annually.

Separately, mRNA vaccine platforms proven during COVID-19 continue to be adapted for other infectious-disease targets, though as of this writing most of that work remains in clinical trials rather than approved use — worth distinguishing from the malaria vaccines above, which are already deployed.

How Do These Breakthroughs Affect Future Doctors and Medical Students?

For NEET aspirants and MBBS students, these breakthroughs are a preview of the clinical toolkit you'll eventually work with — gene-editing therapies, AI-assisted diagnostics, and personalized vaccine platforms are moving from research papers into hospital wards within a single medical-training generation. Universities across our 9 EU partner countries, including Charles University Prague and Semmelweis University Budapest, are increasingly integrating genomics, biotechnology, and digital-health modules into their MBBS curricula to prepare students for this shift.

If you're evaluating where to study medicine with this kind of future-facing curriculum in mind, see our MBBS in Europe guide and partner universities list, or book a free consultation to discuss which of our partner universities fits your interests.

Latest Medical Breakthroughs Transforming Healthcare: Why Verification Matters

Not every headline calling something a medical breakthrough holds up under scrutiny, which is exactly why this rundown of the latest medical breakthroughs transforming healthcare links directly to FDA, WHO, and peer-reviewed sources rather than repeating secondhand claims. Casgevy's approval, the FDA's AI device list, the Lancet-published melanoma vaccine trial, and WHO's malaria vaccine rollout are all independently verifiable — a good habit to apply to any future "breakthrough" story you come across, medical or otherwise.

Sources

• FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease — U.S. Food and Drug Administration: https://www.fda.gov/news-events/press-announcements/fda-approves-first-gene-therapies-treat-patients-sickle-cell-disease

• Artificial Intelligence-Enabled Medical Devices — U.S. Food and Drug Administration: https://www.fda.gov/medical-devices/software-medical-device-samd/artificial-intelligence-enabled-medical-devices

• Weber JS, et al. "Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942)" — PubMed, National Institutes of Health: https://pubmed.ncbi.nlm.nih.gov/38246194/

• Life-saving malaria vaccines reach children in 17 endemic countries in 2024 — World Health Organization: https://www.who.int/news-room/feature-stories/detail/life-saving-malaria-vaccines-reach-children-in-17-endemic-countries-in-2024